Reason for posting: Pioglitazone is an oral hypoglycemic agent widely used as monotherapy or combination therapy for type 2 diabetes mellitus. However, a recent analysis by the drug's manufacturer of several unpublished clinical trials in the company's database revealed an increased risk of bone
No takes yet. Share an insight, caveat, or question.
Meymeh et al. (2007) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: